Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study

Fig. 2

Change from baseline in the Short Form-36 (SF-36) bodily pain score through week 104 (a) and proportion of patients with improvement ≥ 5 in the SF-36 bodily pain domain score (b)

Data are presented as LS mean change using MMRM from weeks 1-24, and observed data are presented from weeks 52-104 (shaded area); P values are calculated from a MMRM analysis (a). Observed data are presented; P values are calculated from Fisher’s exact test (b)

1Number of patients originally randomized to each treatment group. *P < 0.0001; †P < 0.001; ‡P < 0.05 versus placebo. LS, least squares; MMRM, mixed-effect model for repeated measures; PBO, placebo; s.c., subcutaneous; SEC, secukinumab

Back to article page